Product
DF2156A
1 clinical trial
1 indication
Indication
Bullous PemphigoidClinical trial
A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid.Status: Terminated, Estimated PCD: 2012-07-05